866-997-4948(US-Canada Toll Free)

Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Sep 2010

Category :

Therapeutic Area

No. of Pages : 58 Pages


GlobalData has released its pharmaceutical report, Acute Myeloid Leukemia (AML) Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global AML therapeutics market. The report identifies the key trends shaping and driving the global AML therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AML therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData estimated the global AML therapeutics market to be worth $174m in 2009. It is expected to grow to $279m with a Compound Annual Growth Rate (CAGR) of 6.1% by 2017. This growth is primarily attributed to the increase in the prevalence of the disease due to the increasing elderly population and the presence of a strong pipeline with many emerging therapies. Pfizer and Genzyme remain the market leaders within the global AML therapeutics market. There is a high level of unmet need in the current AML therapeutics market in terms of both safety and efficacy.

Scope

The report provides information on the key drivers and challenges of the AML market. Its scope includes: 

  • Annualized global AML market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data provides a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of DNA synthesis inhibitors, HDAC inhibitors, DNA methyltransferase inhibitors and Aurora kinase inhibitors, CD33 antigen targeters, Farnesyl transferase inhibitors and Topoisomerase II inhibitors.
  • Analysis of the current and future competition in the global AML market. The key market players covered are Pfizer, Genzyme, Topo Target A/S, and Vion Pharmaceuticals.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the AML therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines. 
  • Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global AML market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global AML market landscape? Identify, understand and capitalize
Table Of Content

1 Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 AML Therapeutics Market: Introduction 6
2.1 Overview 6
2.2 GlobalData Pipeline Report Guidance 7

3 AML Therapeutics Market: Market Characterization 8
3.1 AML Market Size 8
3.2 AML Therapeutics Market Forecast and CAGR 9
3.3 Secondary AML Patient Volume and Market Size 10
3.4 Overview 10
3.5 Patient Volume 10
3.6 sAML Revenue and Market Forecast 11
3.7 Drivers and Barriers for the AML Therapeutics Market 11
3.7.1 Drivers for the AML Therapeutics Market 11
3.7.2 Barriers for the AML Therapeutics Market 12
3.8 Opportunity and Unmet Need 13
3.9 Key Takeaway 14

4 AML Therapeutics Market: Competitive Assessment 15
4.1 Overview 15
4.2 Strategic Competitor Assessment 15
4.3 Profiles of the Major Marketed Products in the AML Therapeutics Market 16
4.3.1 Cytarabine (cytosine arabinoside) 16
4.3.2 Doxorubicin 17
4.3.3 Daunorubicin (daunomycin cerubidine) 18
4.3.4 Idarubicin (4-demethoxydaunorubicin) 19
4.4 Key Takeaway 22

5 AML Therapeutics Market: Pipeline Assessment 23
5.1 Overview 23
5.2 Strategic Pipeline Assessment 23
5.2.1 Technology Trends Analytic Framework 23
5.3 AML Therapeutics Promising Drugs under Clinical Development 24
5.4 Molecule Profiles for Promising Drugs under Clinical Development 25
5.4.1 AC220 25
5.4.2 Elacytarabine (CP-4055) 25
5.4.3 Clolar 26
5.4.4 Belinostat 27
5.5 AML Therapeutics Market Clinical Pipeline by Mechanism of Action 28
5.6 AML Pipeline Pipeline by Phase of Clinical Development 29
5.6.1 AML Therapeutics Phase III Clinical Pipeline 29
5.6.2 AML Therapeutics Phase II Clinical Pipeline 32
5.6.3 AML Therapeutics Phase I Clinical Pipeline 41
5.6.4 AML Therapeutics Preclinical Pipeline 45
5.7 Key Takeaway 45

6 AML Market: Implications for Future Market Competition 46

7 AML Therapeutics Market: Future Players in the AML Therapeutics Market 47
7.1 Introduction 47
7.2 Genzyme 47
7.2.1 Overview 47
7.2.2 Leukemia Disease Portfolio 49
7.3 TopoTarget A/S 49
7.3.1 Overview 49
7.3.2 Leukemia Disease Portfolio 50

8 AML Market: Appendix 51
8.1 Definitions 51
8.2 Scope of Pipeline Research 51
8.3 KOL Interviews 51
8.4 Acronyms 51
8.5 Research Methodology 53
8.5.1 Coverage 54
8.5.2 Secondary Research 54
8.5.3 Forecasting 54
8.5.4 Primary Research 57
8.5.5 Expert Panel Validation 57
8.6 Contact Us 57
8.7 Disclaimer 57
8.8 Sources 58

List of Table


Table 1: French American British (FAB) Classification of AML, 2010 6
Table 2: AML Therapeutics Market, Global, Revenue ($m), 20012009 9
Table 3: AML Market, Global, Market Forecasts ($m), 20092017 9
Table 4: sAML Patient Volume and Revenue, Global, 20012009 10
Table 5: sAML Patient Volume and Market Forecast, Global, 20092017 10
Table 6: AML Therapeutics Market, Global, Key Combination Regimens for Cytarabine, 2010 16
Table 7: AML Therapeutics Market, Global, CR Comparison Between Idarubicin and Daunorubicin Treatment Regimens, 2010 21
Table 8: Comparison of the Major Marketed Products in the AML Therapeutics Market, 2010 21
Table 9: AML Therapeutics Most Promising Drugs Under Clinical Development, 2010 24
Table 10: AML Therapeutics Phase III Clinical Pipeline, September 2010 29
Table 11: AML Therapeutics Phase II Clinical Pipeline, 2010 32
Table 12: AML Therapeutics Phase I Clinical Pipeline, September 2010 41
Table 13: AML Therapeutics Preclinical Pipeline, 2010 45
Table 14: Genzyme Leukemia Marketed Products, January 2010 49
Table 15: Genzyme Leukemia Pipeline Products, January 2010 49
Table 16: TopoTarget Leukemia Marketed Products, January 2010 50
Table 17: TopoTarget Leukemia Pipeline Products, January 2010 50

List of Chart


Figure 1: AML Therapeutics Market, Global, Revenue ($m), 20012009 8
Figure 2: AML Therapeutics Market, Global, Revenue Forecasts, 20092017 9
Figure 3: sAML Revenue and Market Forecast, Global, 20012017 11
Figure 4: Opportunity and Unmet Need in the AML Therapeutics Market, 2009 13
Figure 5: Strategic Competitor Assessment of the Major Marketed AML Therapeutics, 2010 15
Figure 6: Technology Trends Analytic Framework of the AML Therapeutics Pipeline, 2010 23
Figure 7: Technology Trends Analytic Framework of the AML Therapeutics Pipeline Description, 2010 24
Figure 8: AML Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 28
Figure 9: AML Therapeutics Pipeline by Phase of Clinical Development, 2010 29
Figure 10: Implications for Future Market Competition in the AML Market, 2010 46
Figure 11: AML Therapeutics Market Clinical Pipeline by Company , 2010 47
Figure 12: GlobalData Market Forecasting Model, 2010 56

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *